Ally Bridge Group
Ally Bridge Group is a privately held, founder-controlled global healthcare investment management firm founded in 2013 by Frank Yu, operating dual private equity and long-biased public equity strategies from New York and Hong Kong to deploy over $6 billion in led and co-led healthcare transactions across medtech, biotech, tools/diagnostics, and digital health for institutional limited partners.
- Company typePrivate
- Founded2013
- HeadquartersHong Kong, Hong Kong SAR China
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Ally Bridge Group does
Ally Bridge Group is a privately held, founder-controlled global healthcare investment management firm founded in 2013 by Frank Yu and operating from offices in New York (430 Park Avenue) and Hong Kong (Cheung Kong Center II) through Ally Bridge Group (NY) LLC and Ally Bridge Group (HK) Limited. The firm manages capital across two complementary strategies: a Private Equity platform established in 2013 and a long-biased Public Equity strategy launched in 2018, with stated cumulative led or co-led transaction volume of over $6-7 billion across healthcare subsectors spanning medical technology, biotechnology, single-cell tools and diagnostics, digital health, healthcare services, focused ultrasound, surgical robotics, and antibody-drug conjugates.
The firm's underlying investment platform is its core offering rather than a software product: it combines a scientific and clinical research bench (team includes PharmDs, PhDs, and MDs) with M&A and capital markets expertise to source, underwrite, and lead healthcare financings across the capital structure, from late-stage private rounds (typically targeting companies with $30-50M+ revenue and 50%+ gross margins) through PIPEs and post-IPO positions. Ally Bridge typically invests as a lead or co-lead alongside healthcare-dedicated and generalist sponsors including Longitude Capital, Andera Partners, SoftBank Vision Fund 2, OrbiMed, Bain Capital, Janus Henderson, and Catalio, and holds board seats at multiple portfolio companies (Imperative Care, ProfoundBio, Kestra, Biobeat, Cardiac Dimensions, Epicrispr, VitalConnect, SetPoint, ProMIS).
The revenue model is standard alternative asset management economics: recurring management fees on assets under management across the private and public equity strategies, supplemented by carried interest on private equity funds and performance fees on the public equity strategy. Capital is raised bilaterally from institutional LPs (endowments, family offices, pension funds, sovereign wealth funds) by a dedicated investor relations team led by Managing Director Zain Shekhani for private equity, with portfolio companies serving as investees rather than fee-paying customers. Notable transactions include the WuXi PharmaTech $3.3 billion take-private (2015) and subsequent Hong Kong IPOs of WuXi Biologics (2017) and WuXi AppTec (2018), the CMR Surgical $600 million Series D (2021, co-led with SoftBank Vision Fund 2), Kestra Medical Technologies $196 million (2024), Insightec $150 million (2024), ProMIS Neurosciences up to $175 million PIPE (2026), and ProfoundBio (acquired by Genmab for $1.8 billion in May 2024).
Ally Bridge Group firmographics
Firmographics- Name
- Ally Bridge Group
- Legal name
- Ally Bridge Group (NY) LLC / Ally Bridge Group (HK) Limited
- Website
- http://www.ally-bridge.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ally Bridge Group is a privately held, founder-controlled global healthcare investment management firm founded in 2013 by Frank Yu, operating dual private equity and long-biased public equity strategies from New York and Hong Kong to deploy over $6 billion in led and co-led healthcare transactions across medtech, biotech, tools/diagnostics, and digital health for institutional limited partners.
- Ownership category
- akta.pro rank
Ally Bridge Group industry classification
Industry- Product category
- Healthcare Investment Management
- NAICS
- Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Other Financial Vehicles (52599)
- SIC
- Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)
- akta.pro primary industry
- Cross-Border M&A Advisory (FSAEAGAH)
- akta.pro secondary industries
- Private Sector & Blended Finance Arms (IFC-type) (BPADACAJ), Impact Investment & Development Investment Funds (BPADACAO), Infrastructure & Project Finance Advisory (BPAHADAO)
Keywords
Where Ally Bridge Group is headquartered
LocationHeadquarters
- HQ city
- Hong Kong
- HQ country
- Hong Kong SAR China
- HQ region
- Asia
Offices2 records
Markets served
Ally Bridge Group business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
Revenue model
- Investment management fees: Recurring management fees on assets under management across private equity and public equity fund strategies. Private equity platform established in 2013; public equity long-biased strategy launched in 2018. Standard industry model for alternative asset managers.
- Carried interest / performance fees: Performance-based economics (carried interest on private equity funds and performance fees on public equity strategy) tied to investment outcomes for investors.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Ally Bridge Group product offering
Product offeringCore offering
Ally Bridge Group manages two complementary healthcare-focused investment strategies from offices in New York and Hong Kong: a Private Equity Platform (established 2013) that leads or co-leads growth and late-stage financings across medtech, biotech, tools/diagnostics, and digital health, and a long-biased Public Equity Strategy (launched 2018) that invests across the global healthcare industry. The firm has led or co-led over $6 billion of healthcare transactions and selectively underwrites companies addressing unmet medical needs, blending deep scientific and clinical research with M&A and capital markets expertise.
Product overview
Ally Bridge Group is a global healthcare investment management firm, not a software/product company. Its offering is a two-strategy investment platform composed of the Private Equity Platform (the firm's initial platform, established in 2013) and the Public Equity Strategy (a long-biased strategy launched in 2018). Together, these two complementary strategies allow Ally Bridge Group to invest across the capital structure in private and public healthcare/life science opportunities globally, with assets managed from offices in New York and Hong Kong. The firm seeks to deliver superior risk-adjusted returns by blending deep scientific and clinical research with M&A and capital markets expertise.
Differentiator
Problem solved
Functional benefit
Products and services
- Private Equity Platform Ally Bridge Group's original investment platform, established in 2013, that executes lead or co-lead private investments in healthcare and life science companies across medtech, biotech, tools/diagnostics, digital health, and healthcare services. The firm has led or co-led over $6 billion of healthcare transactions through this platform and selectively underwrites later-stage companies with $30M-$50M+ revenue and 50%+ gross margins addressing unmet medical needs. Targeted at institutional limited partners (LPs) and targeted portfolio companies.
- Public Equity Strategy A long-biased public equity investment strategy launched in 2018, complementing the Private Equity platform. It enables the firm to invest across the global healthcare industry across the capital structure, with public equity leadership based in New York. The strategy invests in publicly traded healthcare companies globally and is overseen by a dedicated CIO (Slanix Paul Alex) and operations/finance team. Targeted at institutional limited partners and the firm's public equity LPs.
Quantifiable outcome
- Over $7 billion of healthcare transactions led or co-led since 2013
- +3 more outcomes
Companies that use Ally Bridge Group
Customer profileSegments3 records
Ideal customer profiles2 records
Ally Bridge Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Ally Bridge Group partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- LifeTech Scientific CorporationflagshipAlly Bridge Group entered into a strategic partnership with LifeTech Scientific Corporation (SEHK) in January 2018 for China-global medtech investment and operating collaboration. The partnership was extended in April 2019 with a three-way China joint venture between Ally Bridge Group, LifeTech Scientific, and Quantum Surgical to develop an innovative surgical robot for liver cancer treatment in China.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Ally Bridge Group competitors and assessment
Company assessmentBroad incumbents
- RA Capital Management: Boston-based healthcare-focused crossover fund that invests across public and private markets and frequently co-invests with Ally Bridge in late-stage biotech and medtech rounds. Most directly comparable in dual public/private healthcare strategy and late-stage investment focus.
- OrbiMed Advisors: Large global healthcare-dedicated investment firm with private equity, public equity, royalties and credit strategies. Directly comparable in healthcare specialization and recurring co-investor alongside Ally Bridge (e.g., Biobeat, Aerin Medical, ProfoundBio, Endeavor BioMedicines).
- Bain Capital Life Sciences: Healthcare-focused arm of Bain Capital investing across the life sciences capital structure. Regular co-investor with Ally Bridge (Imperative Care, Kestra Medical) with significantly larger AUM but the same late-stage healthcare thesis.
- Perceptive Advisors: Healthcare-focused investment manager with life sciences and private credit strategies, frequently co-investing in PIPE and growth rounds with Ally Bridge (ProMIS Neurosciences, Imperative Care convertible, Insightec). Closely comparable as a healthcare-only investor.
- New Enterprise Associates (NEA): Large, multi-stage venture firm with deep healthcare practice across biotech, medtech and digital health. Co-invested with Ally Bridge in TESARO PIPE (2016) and SetPoint Medical, sharing late-stage healthcare exposure at much greater AUM scale.
- TCG Crossover (formerly The Column Group-adjacent) / T. Rowe Price Health Sciences: Healthcare-focused crossover funds that invest across private and public healthcare and frequently co-invest with Ally Bridge (Insightec, Endeavor, ProfoundBio, Kestra Medical). Comparable in crossover mandate and healthcare-only focus at larger scale.
Direct peers
- Longitude Capital: Healthcare-focused growth equity firm investing in late-stage biotech, medtech and digital health. Frequently co-leads rounds with Ally Bridge (e.g., Kestra Medical, Imperative Care) and matches the late-stage, science-driven investment profile.
- Andera Partners: European healthcare-focused growth equity firm (formerly Edmond de Rothschild). Repeated co-lead partner with Ally Bridge on Kestra Medical and other medtech rounds, sharing the late-stage healthcare specialty.
- Omega Funds: Healthcare-dedicated crossover fund investing in biotech and medtech across private and public markets. Co-led Kestra Medical with Ally Bridge and shares the dual-strategy late-stage healthcare thesis.
- Sofinnova Investments: Global healthcare-specialist manager with a long history of biopharma and medtech investment; recently featured alongside Ally Bridge as a 2026 biotech rebound investor. Highly comparable in healthcare-only mandate and public/private crossover activity.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Ally Bridge Group social profiles
Digital presenceAlly Bridge Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ally Bridge Group leadership team
Management profileNumber of profiles
Profiles26 records
Ally Bridge Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ally Bridge Group M&A and investment
M&A and investmentM&A
Investments131 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ally Bridge Group
What does Ally Bridge Group do?
Ally Bridge Group manages two complementary healthcare-focused investment strategies from offices in New York and Hong Kong: a Private Equity Platform (established 2013) that leads or co-leads growth and late-stage financings across medtech, biotech, tools/diagnostics, and digital health, and a long-biased Public Equity Strategy (launched 2018) that invests across the global healthcare industry. The firm has led or co-led over $6 billion of healthcare transactions and selectively underwrites companies addressing unmet medical needs, blending deep scientific and clinical research with M&A and capital markets expertise.
Is Ally Bridge Group a public or private company?
Ally Bridge Group is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Ally Bridge Group founded?
Ally Bridge Group was founded in 2013. It employs 11 to 50 people.
Where is Ally Bridge Group based?
Ally Bridge Group is headquartered in Hong Kong, Hong Kong SAR China, in the Asia region.
How does Ally Bridge Group make money?
Two revenue lines are on record. Investment management fees are the primary driver. The others are carried interest / performance fees.
Who are Ally Bridge Group's main competitors?
Broad incumbents on record are RA Capital Management, OrbiMed Advisors, Bain Capital Life Sciences, Perceptive Advisors, New Enterprise Associates (NEA) and TCG Crossover (formerly The Column Group-adjacent) / T. Rowe Price Health Sciences. Direct peers are Longitude Capital, Andera Partners, Omega Funds and Sofinnova Investments.
Does Ally Bridge Group have an API?
No public API is recorded for Ally Bridge Group.
What industry is Ally Bridge Group in?
Ally Bridge Group's product category is Healthcare Investment Management. Its primary akta.pro industry code is FSAEAGAH, Cross-Border M&A Advisory, with a secondary code of BPADACAJ, Private Sector & Blended Finance Arms (IFC-type). Its NAICS code is 523940 and its SIC code is 6282.